Kangmei Pharmaceutical Co Ltd Market Cap ($2.55 Billion)
Market Cap & Net Worth: Kangmei Pharmaceutical Co Ltd (600518)
Kangmei Pharmaceutical Co Ltd market cap. Kangmei Pharmaceutical Co Ltd (SHG:600518) has a market capitalization of $2.55 Billion (CN¥17.42 Billion) as of October 31, 2026. Listed on the SHG stock exchange, this China-based company holds position #5235 globally and #856 in its home market, demonstrating a -2.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kangmei Pharmaceutical Co Ltd's stock price CN¥1.26 by its total outstanding shares 13828896690 (13.83 Billion).
Kangmei Pharmaceutical Co Ltd Market Cap History (2015–2026)
Kangmei Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows change from $32.97 Billion to $2.59 Billion (-20.37% CAGR). Check 600518 share price today for real-time trading data and today's change.
Index Memberships
Kangmei Pharmaceutical Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Shanghai Shenzhen CSI 300
CSI300
|
$4.00 Trillion | 0.06% | #182 of 285 |
Weight: Kangmei Pharmaceutical Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kangmei Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kangmei Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 600518 cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.91x
Kangmei Pharmaceutical Co Ltd's market cap is 0.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
552.30x
Kangmei Pharmaceutical Co Ltd's market cap is 552.30 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $32.97 Billion | $18.07 Billion | $2.76 Billion | 1.82x | 11.96x |
| 2016 | $35.18 Billion | $21.64 Billion | $3.34 Billion | 1.63x | 10.53x |
| 2017 | $44.48 Billion | $17.58 Billion | $2.15 Billion | 2.53x | 20.69x |
| 2018 | $18.51 Billion | $17.07 Billion | $374.49 Million | 1.08x | 49.44x |
| 2019 | $7.55 Billion | $11.45 Billion | -$4.66 Billion | 0.66x | N/A |
| 2020 | $5.42 Billion | $5.41 Billion | -$31.08 Billion | 1.00x | N/A |
| 2021 | $6.25 Billion | $4.15 Billion | $7.92 Billion | 1.51x | 0.79x |
| 2022 | $4.45 Billion | $4.18 Billion | -$2.69 Billion | 1.07x | N/A |
| 2023 | $3.76 Billion | $4.87 Billion | $102.52 Million | 0.77x | 36.71x |
| 2024 | $4.74 Billion | $5.19 Billion | $8.57 Million | 0.91x | 552.30x |
Competitor Companies of 600518 by Market Capitalization
Companies near Kangmei Pharmaceutical Co Ltd in the global market cap rankings as of October 31, 2026. See Kangmei Pharmaceutical Co Ltd balance sheet quality to understand what proportion of total assets are financed by equity.
Key companies related to Kangmei Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Kangmei Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Kangmei Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Kangmei Pharmaceutical Co Ltd's market cap moved from $32.97 Billion to $ 2.59 Billion, with a yearly change of -20.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.59 Billion | -32.98% |
| 2025 | CN¥3.87 Billion | -18.38% |
| 2024 | CN¥4.74 Billion | +25.81% |
| 2023 | CN¥3.76 Billion | -15.45% |
| 2022 | CN¥4.45 Billion | -28.80% |
| 2021 | CN¥6.25 Billion | +15.30% |
| 2020 | CN¥5.42 Billion | -28.15% |
| 2019 | CN¥7.55 Billion | -59.23% |
| 2018 | CN¥18.51 Billion | -58.38% |
| 2017 | CN¥44.48 Billion | +26.45% |
| 2016 | CN¥35.18 Billion | +6.70% |
| 2015 | CN¥32.97 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Kangmei Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.55 Billion USD |
| MoneyControl | $2.55 Billion USD |
| MarketWatch | $2.55 Billion USD |
| marketcap.company | $2.55 Billion USD |
| Reuters | $2.55 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kangmei Pharmaceutical Co Ltd
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. In addition, it engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical … Read more